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Introduction 
The goal of this research was to develop nuclear medicine imaging agents, to aid in the early 
detection, diagnosis and treatment of breast cancer, based on the epidermal growth factor 
receptor (EGFR) biomarker. EGFR is a member of the ErbB family of receptor tyrosine kinases, 
cell surface receptors responsible for cell proliferation and differentiation. EGF receptors are 
overexpressed in 45% of breast tumors.1 Tumors possessing these receptors fail to respond to 
conventional treatment (hormonal based chemotherapy) leading to decreased patient 
survivability. EGFR based therapeutic agents have been in development by many drug 
companies over the last 10 years.2-4  
Our approach was to design and synthesize small molecule inhibitors of the EGFR tyrosine 
kinase (tk) suitable for labeling with single photon and positron-emitting radioisotopes and 
evaluate the imaging potential of these new molecules. Our selection of the quinazoline 
inhibitors was based on the known structure activity relationships from the work of Fry and 
Bridges at Parke-Davis in the mid 1990’s.5, 6 Several new quinazoline analogs were synthesized. 
The analogs were put through a battery of tests including full chemical characterization, 
assessment of lipophilicity, determination of their ability to inhibit EGFR tk activity and 
measurement of their affinity for the EGFR tk.  Those compounds that possessed suitable 
potency and binding characteristics were radiolabeled and subjected to secondary evaluation in 
in vitro cell studies, in vitro metabolism assays and in vivo distribution studies in tumor bearing 
mice. From this study we have created a library of agent characteristics and established the 
foundation for future research toward the optimal EGFR imaging agent. 
 
Body 
 
Task 1: Months 1-24: Synthesize and characterize new epidermal growth factor tyrosine kinase inhibitors. 
 We have synthesized the 22 quinazoline analogs shown in Figure 2. Four analogs, 10 and 
11 were synthesized during this last year. All of the analogs were synthesized from the 
common intermediates 4-chloro-6,7-dimethoxy- and 4-chloro-6,7-diethoxy-quinazoline by the 
reaction shown in Figure 1. Production of the common intermediates allowed the rapid 
production of new analogs. In many cases the product crystallized out of solution during the 
reaction. The isolated yields from this series of reactions ranged from 65-90%.  All products 
and intermediates were purified and were chemically characterized by NMR, mass 
spectroscopy, melting point and elemental analysis.  
 
Task 2: Months 3-27:  Perform in vitro assays to determine tyrosine kinase affinity and inhibition.  
Measure the lipophilicity of the inhibitors. 
 Mouse BaF3 hematopoietic cells that ectopically express either EGFR, ErbB-2 or ErbB-4 
were pretreated with the kinase inhibitors. Subsequently, the cells were stimulated with EGF 
(for cells expressing EGFR) or Neuregulin (for cells expressing ErbB-2 and ErbB-4). The cells 
were lysed and analyzed for receptor tyrosine phosphorylation by immunoprecipitation with 
anti-EGFR or anti-ErbB antibodies followed by immunoblotting with an anti-phosphotyrosine 
antibody. Inhibition of receptor phosphorylation for 16 of the quinazoline analogs is shown in 
Figure 3.  Additionally, the inhibition of cellular DNA synthesis by the EGFR inhibitors was 
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performed in human mammary tumor MCF-10A cells.  The cells were incubated for 48 hours 
with varying concentrations of the EGFR inhibitors.  Inhibition of DNA synthesis was 
identified by the lack of incorporation of tritiated thymidine into the DNA.  The concentration 
of each inhibitor that inhibits 50% incorporation of the thymidine into the DNA was 
determined.  These assays were performed by Dr. David Riese at Purdue University. 
 Almost all of the quinazoline analogs are potent inhibitors of EGFR tk phosphorylation.  
Most of the compounds exhibit nM inhibition.  The exceptions to this are the 3-bromo-4-
fluorobenzyl analogs, 4a and 4b, and the 3-fluoro-5-trifluoromethyl compound, 9b. The 
compounds were specific for the EGFR tk as demonstrated by the fact that the inhibition of 
ErbB2 and ErbB4 tk phosphorylation was 10-70 fold less than EGFR tk.  In an attempt to find 
a less labor-intensive assay that would be predictive of EGFR tk inhibition, we measured the 
inhibition of DNA synthesis in EGF responsive MCF 10A cells.  In the initial subset of the 
analogs it was found that there was a good correlation between the inhibition of DNA synthesis 
and EGFR tk phosphorylation.  However, as more compounds were tested the DNA synthesis 
inhibition did not significantly correlate with the EGFR tk phosphorylation.  Thus, the DNA 
synthesis assay was not a good predictor of the potency of these compounds. 
 As part of this effort we developed an EGFR tyrosine kinase receptor binding assay.  
Receptor binding of the quinazoline compounds was determined by a competitive radiometric 
assay using [125I]-3’-iodoanailino-6,7-dimethoxy quinazoline as the radioligand.7 
Commercially available A431 human carcinoma cell membrane homogenate was the EGFR 
source (Receptor Biology, Beltsville, MD). By varying the concentration of the quinazoline 
analog, the inhibition of specific binding at the 50% level was determined.  The IC50 values for 
18 of the quinazoline compounds is shown in Figure 5. 
 All of the compounds tested bind to the EGFR tk with high affinity.  The dimethoxy  
analogs of compounds 1a, 8a, 9a, 10a and 11a (4-fluoroanilino, 4-fluorobenzyl, 3-fluoro-5-
trifluoromethylanilino, 2-fluoroanilino and 3-fluoroanilino, respectively) exhibit the lowest 
affinities (IC50 >20 nM). In all cases the affinity of the diethoxy compound is higher than the 
corresponding dimethoxy compound. This is analogous to the reported relationship between 
the diethoxy and dimethoxy compounds in terms of their inhibition of EGFR phosphorylation 
activity (diethoxy > dimethoxy).6 There is not a good correlation between the binding and 
inhibition of phosphorylation (R2=0.36). The binding assay is a more useful as a predictor for 
good imaging agents and is much less cumbersome to perform. 
The lipophilicity of the quinazoline analogs was determined by measuring the 
octanol/water partition coefficients (Log P) for each of the compounds.  The HPLC method of 
Minick, et al.8 was used to determine the Log P (Log [octanol/water]) experimental values.  
The Log P values are shown in Figure 4. The Log P values range from 2.2 for 10a (2-
fluoroanilino-dimethoxyquinazoline) to 5.49 for 9b (3-fluoro-5-trifluoromethylanilino-
diethoxyquinazoline). The data predict the relative changes in lipophilicity between any two 
compounds as would be expected based on the physical differences between the two 
molecules. In general Log P values can be used to predict the non-specific binding of the 
compounds to non-receptor sites. Thus, a compound with a higher Log P might be taken up 
and remain in non-target tissues increasing the background activity and blurring the image.  
The best compounds are generally in the range of 2.0-3.5. 
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Task 3: Months 6-36:  Label receptor tracers with fluorine-18, carbon-11, iodine-123, iodine-125, bromine-
76.  Optimize the synthetic routes for efficient production of high yield, high specific activity tracers. 
 We radioiodinated two of the quinazolines with iodine-125 from the trimethyltin 
precursor. A detailed description of the radiochemistry including the synthesis of the precursor 
is given in the manuscript attached as appendix 10. 
Six compounds were labeled with fluorine-18. These syntheses are shown in Figures 6-8.  
The route to the labeled compounds is analogous to the synthesis of the cold compounds shown 
in Figure 1. Either the labeled benzylamine 13 or the labeled anilines 17 and 21 were coupled 
to the appropriate chloroquinazoline to give the desired labeled compounds. The synthesis of 
the fluorobenzylamine was based on the recently published accounts 9 and the synthesis of the 
fluoroanilines was an adaptation of previous work by Feliu 10. Details of the fluoroaniline work 
are given in Appendix 8. All of the radiolabeled quinazoline compounds were purified by 
HPLC and corresponded in retention time to the non-radioactive analogs.  All compounds were 
produced in 27-30% decay corrected yield for a 155 min. synthesis and purification.  
In addition to alkylating 4-chloroquinazoline with 2- and 4- fluoroaniline and 4-
fluorobenzylamine, we have optimized the production of other fluoroanilines shown in Figure 
9. We have labeled 3-chloro- 27 and 3-bromo-4-[18F]fluoroaniline 28 by reacting cesium 
[18F]fluoride with the respective 4-trimethylammonium triflate . We also produced 3-
[18F]fluoro-nitrobenzene 30 in good yield from the 3-nitrophenyl trimethylammonium triflate 
29. This labeled synthon will allow the production of 3-fluoroanilino compounds.  
 
Task 4: Months 9-36:  Evaluate uptake of labeled tracers in tumor cells possessing differing EGFR titer. 
 We have added [125I]7a to whole MB-468 cells (EGFr +) in suspension and aliquots of 
the media and cells were removed at various times.  The cells were separated from the media 
and each were counted.  A significant portion of the activity remained in the media and no 
change was noted over the time course of the study.   
 Collaborating with Dr. Buck Rogers at the University of Alabama, the time course of 
uptake of [125I]7a and [125I]7b in whole cells that express EGFr (MB468) and those that don’t 
express EGFr (MB453) was examined. The influence of the presence of EGF in the growth 
media and the introduction of blocking doses of non-radioactive 6a was also studied.  The 
results were mixed and inconsistent.  
 A single study was performed using membrane preparations from MB468 cells (EGFr+) 
and MB453 cells (EGFr -). [125I]7a and [125I]7b were added to the preparations with and 
without a blocking dose of 5a. The results of this study are shown in Table 1. The EGFr 
positive membranes take up [125I]7a and [125I]7b and demonstrate receptor mediated uptake in 
the presence of the blocking compound.  The EGFr negative membranes show no binding 
characteristics.  The amount of radiolabel taken up in all cases in the MB453 membranes is 
equivalent to the background (non-specific) seen in the blocked MB468 membranes. This 
study became the basis for the receptor binding assay that was developed (described above). 
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Task 5: Months 18-36:  Evaluate whole body distribution in normal and tumor-bearing nude mice. 
 The distribution of three of the labeled compounds was studied in mice bearing MB468 
tumors, known to overexpress EGFR. The distribution of the compounds is shown in Figures 
10-12. 
 All three compounds demonstrated some uptake in the tumor over the 2 hour study.  In 
all cases there appeared to be washout of the label from the tumor.  The blood values were low 
for the two fluoroanilino compounds, 18a and 18b. The clearance from the blood was most 
evident for compound 14b. The only tumor to blood ratio that increased from 1 to 2 hours was 
that of the fluorobenzyl compound 14b which indicates retention of the compound in the 
tumor. Tumor to muscle ratios for 18a and 18b were less than 1 at all time points whereas the 
tumor to muscle ratios of 14b were greater than 2 to 1 at both time points.  High bone uptake 
was seen for 18a and 18b indicating metabolic defluorination. This is the first time that this 
type of metabolism has been seen with a fluorine-18 labeled compound, however, this type of 
metabolic defluorination of para-fluoro anilines has been described in the literature.11 The 
percent of the injected dose recovered from these animals was very low, on the order of 2-5%.  
This would indicate that the compound is being cleared very rapidly from the body through the 
liver and kidney so that it is not available to bind go to the tumor and bind to the receptors. 
Using cryopresserved hepatocytes from In Vitro Technologies (Baltimore, MD) the 
differences between the metabolism of the 2-[18F fluoroanilino, 22a, and 4-[18F]fluoroanilino, 
18a, positional analogs was investigated. The fluorine-18 labeled compounds were added to 
thawed hepatocytes suspended in Krebs-Hensleit buffer. Compound added to a buffer solution 
with no hepatocytes served as a control. At various time points, aliquots of the solution were 
added to an equivalent amount of methanol and centrifuged to pellet the cells and debris. The 
supernatant liquid was analyzed using thin layer chromatography and HPLC. Figure 13 shows 
the metabolism of the two compounds from the TLC data. The amount of [18F]fluoride ion or 
baseline metabolites was significantly less for the 2-fluoro case indicating limited 
defluorination. This data supports the hypothesis that the 4 position in the anilines is more 
susceptible to defluorination. 
Key Research Accomplishments 
• Synthesized and fully characterized 22 quinazoline analogs including developing a new 
route to the diethoxy compounds.  
• Most of the analogs inhibited epidermal growth factor receptor tyrosine kinase activity at 
pico- or nano-molar concentrations.  
• Analogs tested were selective for the EGFR tk over the ErbB2 tk and the ErbB4 tk. 
• Developed an EGFR tk binding assay and determined the affinity of 18 of the compounds. 
•  14 out of the 18 analogs exhibited high affinity for the EGFR tk receptor. 
• The lipophilicity of the new analogs ranges from 2.2-5.5. 
• Successfully labeled two analogs with iodine-125. 
• Successfully labeled six analogs with fluorine-18. 
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• Optimized the synthesis of labeled fluoroanilines and coupling to the chloroquinazolines. 
• Biodistribution of radiolabeled compounds highlighted delivery and metabolism issues. 
• Solved metabolism issue by synthesizing 2- fluoro compound and testing in isolated 
hepatocytes. 
Reportable Outcomes 
• Abstract presented at the 13th International Symposium on Radiopharmaceutical Chemistry 
entitled “Synthesis of 4-(4’-[18F]fluorobenzylamino)-6,7-diethoxyquinazoline: a positron 
emitting radioprobe for the epidermal growth factor receptor” J. Lab. Comp. Radiopharm. 
42, Suppl. 1:S693-S695, 1999. – Appendix 2. 
• Abstract presented at California Breast Cancer Research Symposium, September 1999 
“Development of PET imaging agents for breast cancer” – Appendix 3. 
• Abstract presented at 219th American Chemical Society National Meeting, March 2000 
“Development of positron labeled epidermal growth factor receptor tyrosine kinase 
inhibitors: PET probes for breast cancer” – Appendix 4. 
• Abstract presented at DoD Era of Hope Meeting, June 2000 
“Development of radiolabeled epidermal growth factor receptor inhibitors.  New probes for 
tumor imaging” – Appendix 5. 
• Abstract presented at 2000 International Chemical Congress of the Pacific Basin Societies, 
December 2000 “Fluorine-18 labeled 4-(4’-fluoroanilino)-6,7-dialkoxy-quinazolines: 
synthesis and evaluation of new breast cancer receptor imaging agents.” – Appendix 6. 
• Abstract presented at 221st American Chemical Society National Meeting, March 2001 
“Novel cancer probes: development of receptor tyrosine kinase-based imaging agents.” – 
Appendix 7. 
• Abstract presented at the 14th International Symposium on Radiopharmaceutical Chemistry 
entitled “Synthesis of [18F]fluoroanilines: precursors to [18F]fluoroanilino-quinazolines.”  J. 
Lab. Comp. Radiopharm. 44, Suppl. 1:S880-882, 2001.– Appendix 8. 
• Abstract to be presented at California Breast Cancer Research Symposium, Fall 2001 
“Epidermal growth factor imaging agents for breast cancer detection and new therapeutic 
drug development.” – Appendix 9. 
• Manuscript: Lim, JK; Negash, K; Hanrahan, SM; VanBrocklin, HF. Synthesis of 4-
(3’[125I]Iodo-phenylamino)-6,7-dialkoxyquinazoline: Epidermal Growth Factor Receptor 
Tyrosine Kinase (EGFrTK) Inhibitors.  J. Lab. Comp. Radiopharm., 43:1183-1191, 2000. – 
Appendix 10. 
• Manuscript: Lim,JK, Hom, DL, Negash, K, Ono, MY, Taylor, SE, Riese II, DJ, 
VanBrocklin, HF.  Quinazoline-based Epidermal Growth Factor Receptor Tyrosine Kinase 
Inhibitors: Development of Tumor Imaging Agents. J. Med. Chem. in preparation.  
• Funding applied for based on this work: NIH RO1 Proposal CA94253 “Targeted Molecular 
Probes for Tumor Imaging”.  
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• Personnel funded through this effort: Henry, F. VanBrocklin, Ph.D. (PI), Scott Taylor, 
Ph.D, James P. O’Neil, Ph.D, Stephen Hanrahan,  
 
Conclusions 
 Over the three years of this project sufficient data has been produced to identify some key 
patterns in the characteristics of these potential imaging agents. While the compounds we have 
developed demonstrate appropriate affinity and specificity for the EGFR tk, the compounds do 
not possess the desired distribution characteristics. The compounds studied may have been too 
lipophilic to cross the cell membrane and as was seen in the case of the 4-fluoroanilino 
compounds, 18a and 18b, metabolic defluorination led to high bone uptake. The 2-fluoroanilino 
compounds that were just synthesized and characterized in this last year possess more desirable 
lipophilic and metabolic characteristics but the binding affinity is 10-30 nM. 
 The biodistribution data of the fluoro compounds corroborates the results from the 
clinical trials of the 3-bromoanilino-dimethoxyquinazoline EGFR inhibitor, 6a. The compound 
cleared rapidly from the body minimizing its potential therapeutic efficacy. In addition to the 
diagnostic potential of these quinazoline analogs, the information that was gathered about the 
distribution properties of these molecules may be very important for the future development of 
tyrosine kinase inhibitors as cancer therapeutics not only for the EGFR but also for ErbB2 and 
VEGF receptors.  
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Appendix 1. 
 
Table 1. Receptor mediated binding of the EGFr tk inhibitors 
 
 Percent of Radiolabel bound to membranes    
Radiolabel MB468 (EGFr+) Membranes MB453 (EGFr-) Membranes   
 (-)6ax (+)6ay (-)6ax (+)6ay 
[125I]7a 72% 26% 28% 29% 
[125I]7b 65% 33% 32% 37% 
x  No blocking dose added to the membranes. 
y Receptor blocking dose added to the membranes. 
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Figure 1. Synthesis of substituted benzyl- and anilino-dialkoxyquinazolines. 
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Figure 2. Dialkoxyquinazoline analogs prepared as part of this effort. 
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Figure 3. Inhibition of EGFR tyrosine kinase phosphorylation. 
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Figure 4. Log P estimation by HPLC for the quinazoline compounds  
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Figure 5. EGF Receptor binding affinity of the quinazoline compounds. 
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Figure 6. Synthesis of 4-(4’-[18F]fluorobenzylamino)-6,7-dimethoxy- and 
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       4-(4’-[18F]fluorobenzylamino)-6,7-diethoxy- quinazoline 
Appendix 1. cont. 
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Figure 7. Synthesis of  4-(4’-[18F]fluoroanalino)-6,7-dimethoxy- and  
 4-(4’-[18F]fluoroanalino)-6,7-diethoxy- quinazoline. 
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Figure 8. Synthesis of 4-(2'-[18F]fluoroanalino)-6,7-dimethoxy- and 4-(2’-[18F]fluoroanalino)-
6,7-diethoxy- quinazoline 
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Figure 9. Synthesis of [18F]fluoroanilines 
Appendix 1. cont. 
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Figure 10.  In vivo distribution of 18a in MDA-468 tumor bearing mice. 
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Figure 11.  In vivo distribution of 18b in MDA-468 tumor bearing mice. 
Appendix 1. cont. 
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Figure 12.  In vivo distribution of 14b in MDA-468 tumor bearing mice. 
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Figure 13. Hepatocyte metabolism kinetic profile of para- (18b) versus ortho- (22b) 
[18F]fluoroanilinodiethoxyquinazoline analogs. Control contained no hepatocytes.  
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